Nexvet Biopharma PLC (NVET) Receives Daily News Sentiment Score of -0.29

News articles about Nexvet Biopharma PLC (NASDAQ:NVET) have been trending negative on Tuesday, Alpha One reports. Alpha One, a division of Accern, rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nexvet Biopharma PLC earned a media sentiment score of -0.29 on Alpha One’s scale. Alpha One also assigned press coverage about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for Nexvet Biopharma PLC (NASDAQ:NVET)

Nexvet Biopharma PLC (NASDAQ:NVET) opened at 6.68 on Tuesday. The company has a 50-day moving average of $6.64 and a 200 day moving average of $4.70. The company’s market cap is $79.60 million. Nexvet Biopharma PLC has a 12 month low of $2.75 and a 12 month high of $6.76.

Nexvet Biopharma PLC (NASDAQ:NVET) last announced its quarterly earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.02. On average, equities analysts forecast that Nexvet Biopharma PLC will post ($1.79) earnings per share for the current fiscal year.

NVET has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of Nexvet Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, April 11th. Credit Suisse Group cut shares of Nexvet Biopharma PLC from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $8.00 to $6.72 in a research report on Monday, April 24th.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/2654688/nexvet-biopharma-plc-nvet-receives-daily-news-sentiment-score-of-0-29.html.

Nexvet Biopharma PLC Company Profile

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NVET”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Nexvet Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.